Pharmaceuticals News and Research

RSS

BioCryst fourth quarter revenues decrease to $5.2 million

BioCryst Pharmaceuticals, Inc. announced financial results for the fourth quarter and full year ended December 31, 2011.

16 Feb 2012

Report illustrates great potential of integrative medicine in chronic health issues

A new survey of 29 integrative medicine centers around the U.S. found that 75 percent reported success using integrative practices to treat chronic pain and more than half reported positive results for gastrointestinal conditions, depression and anxiety, cancer and chronic stress.

16 Feb 2012

Dey Pharma to change company name to Mylan Specialty

Mylan Inc. today announced that it plans to change the name of its fully integrated branded specialty pharmaceutical business from Dey Pharma to Mylan Specialty.

16 Feb 2012

Valeant receives FDA approval for secondary supplier of Methoxsalen

The FDA has approved the addition of a secondary supplier of Methoxsalen USP, an integral component of a treatment for the relief of moderate to severe psoriasis prescribed under the brand name Oxsoralen-Ultra (methoxsalen) Capsules, USP, 10mg.

15 Feb 2012

Counterfeit anti-cancer drug Avastin raises concerns

The market is flooded with a counterfeit version of cancer drug Avastin worry doctors and patients. Injectable drugs have become increasingly attractive to counterfeiters, in part because they often fetch a higher price than regular pills.

15 Feb 2012

VPCI announces successful petition to the FDA for removal from Import Alert

The U.S. Food and Drug Administration (FDA) maintains strict labeling requirements for Active Pharmaceutical Ingredients (APIs). If an API does not maintain adequate labeling as per section 502(f)(1) of the Act, the FDA will consider the material to be misbranded. Foreign APIs which are misbranded are subject to detention without physical examination under FDA's Import Alert 66-66 "Red List."

15 Feb 2012

Teva fourth quarter net revenues increase 28% to $5.7 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter and year ended December 31, 2011.

15 Feb 2012

Nilvadipine phase III trial for Alzheimer's launches in Europe

A research team today announced the launch of a European large-scale clinical trial of Nilvadipine, an Alzheimer's disease drug developed at the Roskamp Institute in Sarasota.

14 Feb 2012

Kowa announces data of LIVALO vs. Crestor on pharmacodynamics of warfarin

Kowa Pharmaceuticals America, Inc. today announced data assessing the effect of LIVALO (pitavastatin) compared with Crestor (rosuvastatin) on steady-state pharmacodynamics (PD) of warfarin by measuring international normalized ratio (INR) in healthy adult subjects.

14 Feb 2012

Scientists create fungi with additional foreign genes to produce chemicals for drugs

Usually, mould fungi are nothing to cheer about - but now they can be used as "chemical factories". Scientists at the Vienna University of Technology have succeeded in introducing bacterial genes into the fungus Trichoderma, so that the fungus can now produce important chemicals for the pharmaceutical industry. The raw material used by the fungus is abundant - it is chitin, which makes up the shells of crustaceans.

14 Feb 2012

Ensysce announces latest data on delivery platform for therapeutic siRNA

Ensysce Biosciences Inc. announced today the publication of their latest data on their delivery platform for short interfering RNA (siRNA) for therapeutic purposes in the journal Materials.

14 Feb 2012

Merck Serono, Mendor sign blood glucose meter distribution agreement

Mendor, the Finnish diabetes technology company, continues its rapid growth and is excited to announce yet another international partnership - now opening the United Kingdom for its innovative products. Mendor has just signed a distribution agreement with a leading pharmaceutical company in the Diabetes field Merck Serono, covering the United Kingdom diabetes market.

14 Feb 2012

Marshall University researcher to understand connections between cancer and obesity

A Marshall University researcher has been awarded a one-year, $60,000 grant from the Pharmaceutical Research and Manufacturers of America (PhRMA) Foundation.

14 Feb 2012

Alnylam commences underwritten public offering of 7,000,000 shares of common stock

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today announced that it has commenced an underwritten public offering of 7,000,000 shares of its common stock. All of these shares are being sold by Alnylam.

14 Feb 2012

Internet addiction, shyness, defiance and grief on bereavement could be mental disorders – Debate on proposed DSM-5

The American Psychiatric Association (APA) has attracted a lot of debate on its proposed amendments to its newest Diagnostic and Statistical Manual of Mental Disorders (DSM) the outlines psychiatric symptoms in the mental-health industry.

13 Feb 2012

Diffusion opens enrollment for TSC clinical trial for newly diagnosed primary brain cancer

Diffusion Pharmaceuticals LLC announced today that it has opened for enrollment a clinical trial testing the company's lead drug candidate trans sodium crocetinate (TSC) as a first-line treatment for newly diagnosed primary brain cancer, also known as glioblastoma or GBM.

13 Feb 2012

Most pharmas concerned over ability to meet EMA EVMPD deadline

Polling conducted by Virtify, Inc. revealed that most pharmaceutical companies are concerned about their ability to comply with the requirement to submit additional pharmacovigilance data to the EMA EudraVigilance Medicinal Product Dictionary (EVMPD) in advance of the July 2, 2012 deadline.

13 Feb 2012

EU-funded 4DCellFate project to kick off today

Today European scientists are meeting to kick off the 4DCellFate project, funded by the European Commission under the FP7 program.

13 Feb 2012

Progesterone vaginal gel 8% NDA transferred to Watson

Columbia Laboratories, Inc., and Watson Pharmaceuticals, Inc., today announced that Columbia has transferred the new drug application for progesterone vaginal gel 8% for use in the reduction of risk of preterm birth in women with a singleton gestation and a short uterine cervical length in the mid-trimester of pregnancy (NDA 22-139) to Watson.

13 Feb 2012

Regeneron reports total revenues of $123.0M for fourth quarter 2011

Regeneron Pharmaceuticals, Inc. announced financial and operating results for the fourth quarter and full year 2011 and provided an update on development programs.

13 Feb 2012